PRESIDENT, PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION (PBOA)
"The pandemic highlighted the key role that CDMOs play, and we need a voice to drive consensus internally, face regulators, and ensure we have a seat at the table."
"In 2019, we opened an office in Elko, Nevada, committing to our local presence and hiring people from the Elko community. We wanted to officially become part of this region."
"Remote projects may prefer to isolate and limit the number of external individuals visiting as a precaution to avoid the virus spreading, but they need to maintain their supply chain so drones are a perfect unmanned logistics solution."
"We wanted to transcend being a gold mining company and tap into a pool of capital much bigger than the gold investment space, which chases dividends and yield."
"Through our association with the University of Nevada, Reno, we are making great efforts to attract skilled graduates into the mining industry and into SRK, since there is currently a large gap in the market."
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.